Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | prostaglandin D2 receptor 2 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily B, polypeptide 6 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily D, polypeptide 6 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 1, subfamily A, polypeptide 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Brugia malayi | cytochrome P450 | cytochrome P450, family 2, subfamily D, polypeptide 6 | 497 aa | 425 aa | 32.0 % |
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | cytochrome P450, family 2, subfamily B, polypeptide 6 | 491 aa | 395 aa | 19.5 % |
Brugia malayi | Cytochrome P450 family protein | cytochrome P450, family 1, subfamily A, polypeptide 2 | 516 aa | 470 aa | 26.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | oxidoreductase | 0.0206 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0206 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0206 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0206 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0206 | 1 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0206 | 1 | 0.5 |
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0206 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0206 | 1 | 0.5 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0206 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0206 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0206 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0206 | 1 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.004 | 0.0701 | 0.0701 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0206 | 1 | 1 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0206 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0206 | 1 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.004 | 0.0701 | 1 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0206 | 1 | 0.5 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0206 | 1 | 1 |
Trypanosoma brucei | Monooxygenase, putative | 0.0206 | 1 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0206 | 1 | 0.5 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0206 | 1 | 0.5 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0206 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0206 | 1 | 0.5 |
Echinococcus granulosus | protein MICAL 3 | 0.0206 | 1 | 0.5 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0206 | 1 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0206 | 1 | 1 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0206 | 1 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0206 | 1 | 1 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0206 | 1 | 0.5 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0206 | 1 | 0.5 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0206 | 1 | 1 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0206 | 1 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0206 | 1 | 0.5 |
Schistosoma mansoni | monoxygenase | 0.0206 | 1 | 0.5 |
Echinococcus multilocularis | protein MICAL 3 | 0.0206 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP1A2 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP2B6 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
IC50 (ADMET) | > 10 uM | Inhibition of human recombinant CYP2D6 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry | ChEMBL. | 24900284 |
Ki (binding) | = 2.4 nM | Displacement of [3HPGD2 from human CRTH2 receptor expressed in CHO cell membrane after 90 mins by scintillation proximity assay | ChEMBL. | 24900284 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.